Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate)
Normal Appearing and Diffusely Abnormal White Matter in Patients with Multiple Sclerosis Assessed with Quantitative MR.
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158N murine oligodendrocytes.
Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia.
RTL therapy for multiple sclerosis: a Phase I clinical study.
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.
Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
Dilantin
Opinion: Sex inclusion in basic research drives discovery.
FDA approval announcement for ofatumumab
Gordon Research Conference on Glia Biology: Functional Interactions among Glia & Neurons
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC)
Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Pages